Status:
RECRUITING
CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
Lead Sponsor:
Beijing 302 Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
30-80 years
Brief Summary
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cir...
Eligibility Criteria
Inclusion
- Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
- Unfeasible or refusing to undergo other treatments;
- Residual normal liver volume ≥700 cc;
- With decompensated cirrhosis (Child-Pugh B or C classification);
- Without portal vein tumor thrombus;
- Eastern Cooperative Oncology Group (ECOG) score 0-1;
- Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm；
- Rejecting other therapies such as resection, liver transplantation, etc.
- Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
- Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.
Exclusion
- With Tumor thrombus；
- With extrahepatic metastasis;
- With lymph node involvement.
Key Trial Info
Start Date :
August 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04512833
Start Date
August 12 2020
End Date
August 30 2026
Last Update
June 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing 302 hospital
Beijing, China, 100039